Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents

Pharmacology Biochemistry and Behavior

Volumn 88, Issue 3, 2008, Pages 358-365

  Fantegrossi, William E ^a   Reissig, Chad J ^b   Katz, Elyse B ^a   Yarosh, Haley L ^a   Rice, Kenner C ^c   Winter, Jerrold C ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Drug discrimination; Hallucinogens; Head twitch response; Serotonin receptors

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; LYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N,N DIPROPYLTRYPTAMINE; PSILOCYBINE; TRYPTAMINE; UNCLASSIFIED DRUG;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HALLUCINOGENS; LYSERGIC ACID DIETHYLAMIDE; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERAZINES; PIPERIDINES; PSILOCYBINE; PYRIDINES; RATS; RATS, INBRED F344; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; TRYPTAMINES;

MUS; RATTUS; RODENTIA;

EID: 36248936052     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.09.007     Document Type: Article

References (46)

1. Aghajanian G.K., and Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 21 2S (1999) 16S-23S
2. Appel J.B., West W.B., Rolandi W.G., Alici T., and Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 64 2 (1999) 353-358
3. Boulton C.S., and Handley S.L. Factors modifying the head-twitch response to 5-hydroxytryptophan. Psychopharmacologia 31 3 (1973) 205-214
4. Chemel B.R., Roth B.L., Armbruster B., Watts V.J., and Nichols D.E. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology 188 2 (2006) 244-251
5. Colpaert F.C., and Janssen P.A.J. The head twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22 8 (1983) 993-1000
6. Corne S.J., and Pickering R.W. A possible correlation between drug-induced hallucinations in man and a behavioral response in mice. Psychopharmacologia 11 (1967) 65-78
7. Corne S.J., Pickering R.W., and Warner B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol 20 (1963) 106-120
8. 2 receptor-induced head-twitch behavior in mice. Eur J Pharmacol 186 (1990) 115-118
9. 2 receptors?. Pharmacol Biochem Behav 36 (1990) 901-906
10. Darmani N.A., Martin B.R., and Glennon R.A. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J Pharmacol Exp Ther 262 2 (1992) 692-698
11. Eison A.S., and Yocca F.D. Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 111 3 (1985) 389-392
12. Fantegrossi W.E., Kiessel C.L., Leach P.T., Martin C.V., Karabenick R.L., Chen X., et al. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology 173 3-4 (2004) 270-277
13. Fantegrossi W.E., Harrington A.W., Eckler J.R., Arshad S., Rabin R.A., Winter J.C., Coop A., et al. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology 181 3 (2005) 496-503
14. Fantegrossi W.E., Harrington A.W., Kiessel C.L., Eckler J.R., Rabin R.A., Winter J.C., et al. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83 1 (2006) 122-129
15. Fiorella D., Rabin R.A., and Winter J.C. Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives. Psychopharmacology 121 3 (1995) 357-363
16. Fiorella D., Rabin R.A., and Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: antagonist correlation analysis. Psychopharmacology 121 3 (1995) 347-356
17. Fiorella D., Helsley S.E., Lorrain D.S., Palumbo P.A., Rabin R.A., and Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology 121 3 (1995) 364-372
18. Fozard J.R., and Palfreyman M.G. Metoclopramide antagonism of 5-hydroxytryptophan-induced "wet-dog" shake behaviour in the rat. Naunyn Schmiedebergs Arch Pharmacol 307 2 (1979) 135-142
19. Glennon R.A., Young R., Jacyno J.M., Slusher M., and Rosecrans J.A. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 86 3-4 (1983) 453-459
20. Gonzalez-Maeso J., Yuen T., Ebersole B.J., Wurmbach E., Lira A., Zhou M., et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23 26 (2003) 8836-8843
21. Gonzalez-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53 3 (2007) 439-452
22. Goodwin G.M., and Green A.R. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84 3 (1985) 743-753
23. 2 receptor antagonist pirenperone. Neuropharmacology 22 (1983) 573-578
24. Handley S.L., and Singh L. Neurotransmitters and shaking behavior: more than a "gut bath" for the brain. Trends Pharmacol Sci 7 (1986) 324-328
25. Leonhart M.M. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. Fed Regist 69 188 (2004) 58050-58053
26. Lucki I., Nobler M.S., and Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 228 (1984) 133-139
27. McKenna D.J., Repke D.B., and Peroutka S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropsychopharmacology 29 (1990) 193-198
28. Nagai F., Nonaka R., and Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559 2-3 (2007) 132-137
29. Nichols D.E. Role of serotonergic neurons and 5-HT receptors in the action of hallucinogens. In: Baumgarten H.G., and Gothert M. (Eds). Serotonergic Neurons and 5-HT Receptors in the CNS (1999), Springer, Berlin 563-585
30. Nichols D.E. Hallucinogens. Pharmacol Ther 101 (2004) 131-181
31. Ortmann R., Biscoff S., Radeke E., Bueche O., and Delini-Stula A. Correlation between different measures of antiserotonin activity of drugs. Naunyn Schmiedebergs Arch Pharmacol 321 (1982) 265-270
32. Peroutka S.J., Lebovitz R.M., and Snyder S.H. Two distinct central serotonin receptors with different physiological functions. Science (Wash DC) 212 (1981) 827-829
33. 1A receptor and the stimulus effects of LSD in the rat. Psychopharmacology 182 2 (2005) 197-204
34. 2 receptors: Implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98 4 (1989) 495-499
35. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275 1 (1995) 101-113
36. Shulgin A., and Shulgin A. TIHKAL: the Continuation (1991), Transform Press, Berkley 527-531
37. Soskin R.A. Dipropyltryptamine in psychotherapy. Curr Psychiatr Ther 15 (1975) 147-156
38. Soskin R.A., Grof S., and Richards W.A. Low doses of dipropyltryptamine in psychotherapy. Arch Gen Psychiatry 28 6 (1973) 817-821
39. Thiagaraj H.V., Russo E.B., Burnett A., Goldstein E., Thompson C.M., and Parker K.K. Binding properties of dipropyltryptamine at the human 5-HT1a receptor. Pharmacology 74 4 (2005) 193-199
40. Winter J.C. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. J Pharmacol Exp Ther 204 (1978) 416-423
41. Winter J.C., and Rabin R.A. Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacol Biochem Behav 30 (1988) 617-624
42. Winter J.C., Fiorella D.J., Timineri D.M., Filipink R.A., Helsley S.E., and Rabin R.A. Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64 2 (1999) 283-293
43. 1A receptors. Pharmacol Biochem Behav 65 (2000) 75-82
44. Winter J.C., Eckler J.R., and Rabin R.A. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with phencyclidine and LSD as discriminative stimuli. Psychopharmacology 172 (2004) 233-240
45. Winter J.C., Rice K.C., Amorosi D.J., and Rabin R.A. Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav 87 4 (2007) 472-480
46. Yocca F.D., Wright R.N., Margraf R.R., and Eison A.S. 8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats. Pharmacol Biochem Behav 35 1 (1990) 251-254